Abstract:Treatment-resistant asthma remains an unresolved clinical problem and a challenge for current medical science. Consequently, there is a growing and urgent need to develop novel or alternative therapeutic options for the treatment of asthma. The research problem raised in this study was to assess and compare mycophenolate mofetil (MMF), an inhibitor of inosine monophosphate dehydrogenase, and tofacitinib (TFB), a Janus kinase inhibitor, for anti-asthmatic properties, and consequently to determine whether these agents may have potential as alternative options for treatment of allergic asthma. For this purpose, we assessed the effect of administration of MMF and TFB on the development of a mouse model of allergic airway inflammation (AAI) and accompanying CD4+ (cluster of differentiation 4) T-cell immune response in the lung-draining mediastinal lymph nodes (MLNs) and lungs, i.e., in the inductive and effector sites, respectively, of the immune response underlying the development of allergic asthma. The results from a histopathological scoring system demonstrated that the administration of MMF and TFB did not prevent or abolish ovalbumin-induced AAI, but strongly attenuated its severity. The pulmonary function tests revealed that the treatment with MMF and TFB significantly reduced methacholine-induced bronchoconstriction. These results indicate that the treatment with TFB and MMF attenuated the development of ovalbumin-induced AAI. The magnitude of the anti-asthmatic effect was comparable between both agents. The study revealed that the impairment of the clonal expansion of effector CD4+ T cells in the MLNs is a critical event in the mechanism underlying the anti-asthmatic effect of MMF and TFB. Apart from this, the findings of the study strongly suggest that the suppression of the interleukin-33/suppression of tumorigenicity-2 signaling pathway may constitute an additional mechanism responsible for producing this effect. In turn, the results indicate that the anti-asthmatic action induced by the studied agents is not mediated by the generation of forkhead box protein 3-expressing CD4+ regulatory T cells. Clinical implication of the results: the results suggest that MMF and TFB may exert anti-asthmatic action, and thus they may be considered therapeutic options for the treatment of allergic asthma cases resistant to conventional/existing treatment.

The AKT Inhibitor MK2206 Suppresses Airway Inflammation and the Pro‑remodeling Pathway in a TDI‑induced Asthma Mouse Model.

Study on Cysteinyl Leukotriene Receptor Antagonist Depressing Acute Asthma Airway Inflammation

Effect of MKK34 on airway β-catenin in a HDM-induced mouse asthma

Inhibition of P21-Activated Kinase 1 Attenuates the Cardinal Features of Asthma Through Suppressing the Lymph Node Homing of Dendritic Cells.

DEK‐targeting Aptamer DTA‐64 Attenuates Bronchial EMT‐mediated Airway Remodelling by Suppressing TGF‐β1/Smad, MAPK and PI3K Signalling Pathway in Asthma

Blockade of Β-Catenin Signaling Attenuates Toluene Diisocyanate-Induced Experimental Asthma.

PI3K/AKT/mTOR and TLR4/MyD88/NF-κB Signaling Inhibitors Attenuate Pathological Mechanisms of Allergic Asthma

Mitoquinone Ameliorated Airway Inflammation by Stabilizing Β-Catenin Destruction Complex in a Steroid-Insensitive Asthma Model.

BMS‑345541 Inhibits Airway Inflammation and Epithelial‑mesenchymal Transition in Airway Remodeling of Asthmatic Mice.

Bongkrekic acid alleviates airway inflammation via breaking the mPTP/mtDAMPs/RAGE feedback loop in a steroid-insensitive asthma model

A Study on the Effects of Cysteinyl Leukotriene Receptor Antagonist and Dexamethasone on the Transcription Level of Arginase - I in Asthmatic Mouse Models

Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway

Novel benzofuran derivative DK-1014 attenuates lung inflammation via blocking of MAPK/AP-1 and AKT/mTOR signaling in vitro and in vivo

Mycophenolate Mofetil, an Inhibitor of Inosine Monophosphate Dehydrogenase, and Tofacitinib, a Janus Kinase Inhibitor, Attenuate Airway Inflammation and Hyperresponsiveness in a Mouse Model of Allergic Asthma

Andrographolide restores healthy airway function in toluene diisocyanate‐induced occupational mouse asthma model through upregulation of heam oxygenase‐1 and activation of Akt/Nrf‐2 dependent pathway

Prevention of IL-6 signaling ameliorates toluene diisocyanate-induced steroid-resistant asthma

The MNK-1/eIF4E Pathway As a New Therapeutic Pathway to Target Inflammation and Remodelling in Asthma.

Midkine-Notch2 Pathway Mediates Excessive Proliferation of Airway Smooth Muscle Cells in Chronic Obstructive Lung Disease

[Dek-Targeting Aptamer DTA-64 Inhibits Epithelial-Mesenchymal Transition of Airway Epithelial Cells in Bronchial Asthmatic Mice Via Blocking TGF-β1 Signaling Pathway].

Effects of Korean medicine Mahuang Dingchuan Decoction on MAPKs/NF-κB/VEGF signaling pathway in asthmatic mice

CKD-497 inhibits NF-kB signaling and ameliorates inflammation and pulmonary fibrosis in ovalbumin-induced asthma and particulate matter-induced airway inflammatory diseases